icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
eNrdWF1v2jAUfedXRHl3EigUOgWqjbUbUqsyWrRpL5VxLmBm4tQflO7Xz0noRqdEbU390hdk7Pjca/uec68dn27XzNuAkJSnfb8ZRL4HKeEJTRd9f3pzjnr+6aARr/AG733WDaKg2fI9wrCUfT8fDWaAUxn8uLz4DGY+CH/Q8GI+WwFRT77TirLgK5bLS5zl33jxhtPEW4Na8qTvZ1oVvV4slTBeDO65+CUzTCAOdz37o6vb9n5/HOZgL0DVEsQFTheVoHNhhUm0EJCqIVaw4OKhxt8jK2wqJyC5FgTGWC3Hgm9oAkm195hJsDIyv0+uQWwYqNxIJXi4ImtpBY5XeDuBu1G10x/N6FBtFYpQs9s5bvWanU6r3YmsTIm9rao+BbOIMLs96nSik+5JOBdhAoTmwY1S1IpabRS1ulGYkFDCGiUaNSPEieIzAeWw6SKcMVgASgAxjJZYK0Dmhwuqik6JU9PIuFCmgQTMtUQJwoSARJkwHCGPc2VmjGNWzNMZ3ZoYKhpMr/HMMlrGuV3mKE6oHD4NdUd2BNw9G48JlRnDD8FKZrZbhQU2wyCMILlbSL6CG2Ekkpk9+w8/1YyFr/R6uhMwRx7n+jjkOlU1OnY+sd2IITe82NafqJ30qu0uFinIt4P9zdPqtDPWM0aJrcgaGdQg1XQyqtfY9y1Pn7CEqXCnT99pmvB7+fa6tx9njrwvzoRVg5LbVq/b7h0fWZP6pwnpmhx8pgXPIDR6SOUhMjdK5/xQgTMsqYZ65Mg7pkdRm3KCGdRUp8hSfQ0vHotpZ8xzx+pyoBL0y9mNbcB+0yAerou/ldA06f8NNbvU5CLfGXrUOv56spWK4+TeokW1ki2VyuSHMFxiWXItMDR+/3lvr/hxd4dzUmGVFWeZPRy5PiuLgpfHiy3nn6u/Dr1T7Obv7i6VNpTQcMA5lOnBmYiPzt4+L/y7UDhze/xEx9yZKYp/rIwuuSoB9awS8bBMZM41PRdGHK7mc1rznlYbl3FYvuUNGnGYv+MNGn8ApVGuRg==
g39wFgV3HKu7acUj